Figures
In Fig 6, the x-axis label for the IAV row in panel C is incorrect. The authors have provided a corrected version of Fig 6 here.
Treatments (itaconate, 20 mM; DI 0.5 mM; 4OI 125 μM) were applied as indicated to dTHP1 cells infected with IAV (PR8M, MOI = 1), and analyses performed 12 h p.i. A. Itaconate, DI, and 4OI inhibit STAT1 phosphorylation, but only DI and 4OI inhibit AKT phosphorylation (immunoblot for the indicated targets, using β-actin as internal control). B. 4OI exerts the strongest ACOD1 mRNA reduction (RT-qPCR, n = 3). Reference for fold change = uninfected cells 12 h. C. The three itaconates reduce IAV-induced mitochondrial ROS levels to a similar degree (flow cytometry, n = 3). Mean ±SEM *p<0.05; **p<0.01; ***p<0.001 (1-way ANOVA followed by Tukey’s multiple comparison test).
Reference
- 1. Sohail A, Iqbal AA, Sahini N, Chen F, Tantawy M, Waqas SF, et al. (2022) Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection. PLoS Pathog 18(1): e1010219. https://doi.org/10.1371/journal.ppat.1010219 pmid:35025971
Citation: Sohail A, Iqbal AA, Sahini N, Chen F, Tantawy M, Waqas SFH, et al. (2022) Correction: Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection. PLoS Pathog 18(11): e1011002. https://doi.org/10.1371/journal.ppat.1011002
Published: November 29, 2022
Copyright: © 2022 Sohail et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.